QSAR investigation of new cognition enhancers

QSAR and Combinatorial Science

Volumn 28, Issue 10, 2009, Pages 1123-1129

  Dearden, John C ^a   Hewitt, Mark ^a   Geronikaki, Athina A ^b   Garibova, Taissia L ^c   Macaev, Fliur Z ^d   Voronina, Tatiana A ^c  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^d INSTITUTE OF CHEMISTRY   (Moldova)

Author keywords

Amnesia test; Cognition enhancers; Drug design; Hydrogen bonds; Multiple linear regression; No tropic drugs; QSAR

Indexed keywords

4 (CHLOROBENZYLIDEN)THIAZOL 2 YLAMINE; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DEMENTIA; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; EXTERNAL VALIDITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

EID: 77049106101     PISSN: 1611020X     EISSN: 16110218     Source Type: Journal    
DOI: 10.1002/qsar.200860152     Document Type: Article

References (30)

1. A. Wimo, L. Jonsson, B. Winblad, Dementia and Geriatric Cognitive Disorders 2006, 21, 175-181.
2. K. Maslow, Alzheimers & Dementia 2008, 4, 110-133.
3. I. Maidment, S. Guy, D. Branford, Pharmaceut. J. 2008, 280, 686.
4. C. Lanni, S. C. Lenzken, A. Pascale, I. Del Vecchio, M. Racchi, F. Pistoia, S. Govoni, Pharmacol. Res. 2008, 57, 196-213.
5. B. Sahakian, S. Morain-Zamir, Nature 2007, 450, 1157-1159.
6. A. A. Geronikaki, J. C. Dearden, D. Filimonov, I. Galaeva, T. L. Garibova, T. Gloriozova, V. Krajneva, A. Lagunin, F. Z. Macaev, G. Molodavkin, V. V. Poroikov, S. I. Pogrebnoi, F. Shepeli, T. A. Voronina, M. Tsitlakidou, L. Vlad, J. Med. Chem. 2004, 47, 2870-2876.
7. http://www.ibmc.msk.ru/PASS
8. V. V. Poroikov, D. A. Filimonov, Yu.V. Borodina, A. A. Lagunin, A. Kos, J. Chem. Inf. Comput. Sci. 2000, 40, 1349-1355.
9. A. V. Stepanchikova, A. A. Lagunin, D. A. Filimonov, V. V. Poroikov, Curr. Med. Chem. 2003, 10, 225-233.
10. V. Poroikov, D. Filimonov, A. Lagunin, T. Gloriozova, A. Zakharov, SAR QSAR Environ. Res. 2007, 18, 101-110.
11. http://www.lhasalimited.org
12. C. A. Marchant,, K. A. Briggs, A. Long, Toxicology Mechanisms Meth. 2008, 18, 177-187.
13. M. R. Doddareddy, Y. S. Cho, H. Y. Koh, A. N. Pae, Bioorg. Med. Chem. 2004, 12, 3977-3985.
14. S. Avram, A. L. Milac, D. F. Mihailescu, A. Dabu, M. L. Flonta, Curr. Enzyme Inhib. 2006, 2, 311-328.
15. V. Lather, A. K. Madan, J. Mol. Struct. (Theochem) 2004, 678, 1-9.
16. S. Bachurin, S. Tkachenko, I. Baskin, N. Lermontova, T. Mukhina, L. Petrova, A. Ustinov, A. Proshin, V. Grigoriev, N. Lukoyanov,V. Palyulin, N. Zefirov, Ann. New York Acad. Sci. 2001, 939, 219-236.
17. C. N. Eid, G. G. Kinney, in Burger's Medicinal Chemistry and Drug Discovery, 6th ed., Vol. 6 (Ed: D. J. Abraham), Wiley-Interscience, Hoboken, NJ 2003, pp. 779-835.
18. J. L. Jenkins, A. Bender, J.W. Davies, Drug Discovery Today 2006, 3, 413-421.
19. M. N. Romanelli, P. Gratteri, L. Guandalini, E. Martini, C. Bonaccini, F. Gualtieri, ChemMedChem 2007, 2, 746-767.
20. A. Marwaha, R. K. Goel, M. P. Mahajan, Bioorg. Med. Chem. Lett. 2007, 17, 5251-5255.
21. T. A. Voronina, Soviet Med. Rev., Sect. G: Neuropharmacol. Rev. 1992, 2, 51-106.
22. R. Cumin, E. F. Bandle, E. Gamzu, W. E. Haefely, Psychopharmacology 1982, 78, 104-111.
23. R. Ader, P. Moleman, J. A.W. Weijnen, Psychonomic Sci. 1972, 26, 125-126.
24. http://www.accelrys.com
25. http://software.timtec.net/hybot-plus.htm
26. http://www.fqs.pl
27. http://research.chem.psu.edu/pcjgroup/adapt.html
28. http://www.talete.mi.it/mobydigs.htm
29. L. Eriksson, J. Jaworska, A. P. Worth, M. T.D. Cronin, R. M. McDowell, P. Gramatica, Environm. Health Perspectives 2003, 111, 1361-1375.
30. A. Golbraikh, A. Tropsha, J. Mol. Graphics Modell. 2002, 20, 269-276.